Since their FDA approval in 2013, sodium-glucose cotransporter-2 inhibitors (SGLT2) have been primarily recognized as glucose-lowering agents for patients with type 2 diabetes mellitus (T2DM) by promoting glucose excretion through the urine [3]. This evidence concerns the gene SLC5A2 and diabetes mellitus.